ECSP11011033A - Virus sincitial respiratorio vivo atenuado - Google Patents

Virus sincitial respiratorio vivo atenuado

Info

Publication number
ECSP11011033A
ECSP11011033A EC2011011033A ECSP11011033A ECSP11011033A EC SP11011033 A ECSP11011033 A EC SP11011033A EC 2011011033 A EC2011011033 A EC 2011011033A EC SP11011033 A ECSP11011033 A EC SP11011033A EC SP11011033 A ECSP11011033 A EC SP11011033A
Authority
EC
Ecuador
Prior art keywords
rsv
attened
lived
synthetic virus
respiratory synthetic
Prior art date
Application number
EC2011011033A
Other languages
English (en)
Spanish (es)
Inventor
Xian Liang
Mary K Yagodich
Michael P Citron
Daniel J Distefano
David L Krah
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of ECSP11011033A publication Critical patent/ECSP11011033A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18564—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
EC2011011033A 2008-11-05 2011-05-05 Virus sincitial respiratorio vivo atenuado ECSP11011033A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19832708P 2008-11-05 2008-11-05

Publications (1)

Publication Number Publication Date
ECSP11011033A true ECSP11011033A (es) 2011-12-30

Family

ID=41527812

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011033A ECSP11011033A (es) 2008-11-05 2011-05-05 Virus sincitial respiratorio vivo atenuado

Country Status (19)

Country Link
US (1) US9011876B2 (https=)
EP (1) EP2346990B1 (https=)
JP (2) JP5016731B2 (https=)
KR (1) KR20110063863A (https=)
CN (1) CN102272295A (https=)
AU (1) AU2009311287C1 (https=)
BR (1) BRPI0921424A2 (https=)
CA (1) CA2742086A1 (https=)
CL (1) CL2011000999A1 (https=)
CO (1) CO6362047A2 (https=)
EC (1) ECSP11011033A (https=)
IL (1) IL212437A0 (https=)
MA (1) MA32878B1 (https=)
MX (1) MX2011004719A (https=)
PE (1) PE20110394A1 (https=)
RU (1) RU2011122615A (https=)
TN (1) TN2011000182A1 (https=)
WO (1) WO2010053883A1 (https=)
ZA (1) ZA201103259B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9011876B2 (en) * 2008-11-05 2015-04-21 Merck Sharp & Dohme Corp. Live, attenuated respiratory syncytial virus
US20140242669A1 (en) * 2011-08-18 2014-08-28 Ycine Llc Production of infectious rna viruses in yeast
JP6085886B2 (ja) 2011-08-29 2017-03-01 国立大学法人徳島大学 Ｒｓｖ粘膜ワクチン
EP4190895A1 (en) * 2013-02-08 2023-06-07 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization
EP3798310A1 (en) * 2013-03-14 2021-03-31 Emory University Recombinant rsv with silent mutations, vaccines, and methods related thereto
EP3057978B1 (en) 2013-10-16 2022-09-14 Merck Sharp & Dohme LLC Method of microwave vacuum drying spherical-shaped pellets of biological materials
WO2015057548A1 (en) 2013-10-16 2015-04-23 Merck Sharp & Dohme Corp Thermostable respiratory synctial virus (rsv) vaccine compositions
US10947512B2 (en) * 2015-08-14 2021-03-16 Research Institute At Nationwide Children's Hospital Respiratory syncytial virus having altered NS1 protein function and related materials and methods
MX2018005462A (es) 2015-10-29 2018-08-01 Univ Emory Composiciones inmunogénicas de rsv quimérico y métodos de uso.
JP7198759B2 (ja) 2016-09-23 2023-01-04 ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンテッド・バイ・ザ・セクレタリー・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシーズ 弱毒化表現型を有するヒト呼吸器多核体ウイルス（ｒｓｖ）のためのワクチン候補
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
CN111344008A (zh) * 2017-09-15 2020-06-26 俄亥俄州创新基金会 用于预防呼吸道合胞病毒(rsv)感染的疫苗及其制备和使用方法
TW202535439A (zh) * 2023-11-17 2025-09-16 美商賽諾菲巴斯德公司 海藻糖疫苗調配物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038138A1 (en) * 1996-04-04 1997-10-16 The Regents Of The University Of Michigan Attenuated respiratory syncytial virus
CA2323927A1 (en) 1998-03-26 1999-09-30 American Cyanamid Company Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b
ATE419369T1 (de) 1999-07-09 2009-01-15 Us Gov Health & Human Serv Chimäre mensch-rinder respiratory syncytial virus vakzinen
JP2007531491A (ja) 2002-09-27 2007-11-08 メディミューン・ヴァクシンズ・インコーポレーテッド 呼吸器合胞体ウイルスにおける機能的突然変異
EP1613345B1 (en) * 2003-03-28 2010-05-26 MedImmune, LLC Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
JPWO2008096811A1 (ja) * 2007-02-07 2010-05-27 ディナベック株式会社 弱毒化マイナス鎖ｒｎａウイルス
US9011876B2 (en) * 2008-11-05 2015-04-21 Merck Sharp & Dohme Corp. Live, attenuated respiratory syncytial virus

Also Published As

Publication number Publication date
US9011876B2 (en) 2015-04-21
JP5743794B2 (ja) 2015-07-01
JP2011250798A (ja) 2011-12-15
MA32878B1 (fr) 2011-12-01
MX2011004719A (es) 2011-05-31
CL2011000999A1 (es) 2012-07-20
PE20110394A1 (es) 2011-06-22
IL212437A0 (en) 2011-06-30
EP2346990A1 (en) 2011-07-27
AU2009311287A1 (en) 2010-05-14
EP2346990B1 (en) 2016-01-06
WO2010053883A1 (en) 2010-05-14
RU2011122615A (ru) 2012-12-20
ZA201103259B (en) 2012-01-25
CA2742086A1 (en) 2010-05-14
JP2012507302A (ja) 2012-03-29
BRPI0921424A2 (pt) 2016-01-05
KR20110063863A (ko) 2011-06-14
AU2009311287B2 (en) 2013-02-07
TN2011000182A1 (en) 2012-12-17
AU2009311287C1 (en) 2015-02-19
CO6362047A2 (es) 2012-01-20
CN102272295A (zh) 2011-12-07
JP5016731B2 (ja) 2012-09-05
US20110212130A1 (en) 2011-09-01

Similar Documents

Publication Publication Date Title
ECSP11011033A (es) Virus sincitial respiratorio vivo atenuado
UY32457A (es) Vacuna del virus del dengue inactivado
CY1124742T1 (el) 4'-φθορο-νουκλεοσιδια, 4'-φθορο-νουκλοεοτιδια και αναλογα αυτων για τη θεραπευτικη αγωγη toy hcv
GT201500005A (es) Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue
CR20160337A (es) Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b
UY36465A (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
CL2013002379A1 (es) Virus del sindrome reproductor y respiratorio porcino (prrsv); procedimiento para la preparacion del prrsv atenuado vivo; vacuna que lo comprende y su procedimiento de preparacion; y procedimiento para inmunizar cerdos contra el sindrome reproductor y respiratorio porcino.
EA201270063A1 (ru) Рекомбинантные антигены pcb
CO6630147A2 (es) Modificador del sabor dulce
CL2019001200A1 (es) Vacuna contra el parvovirus porcino y el virus del síndrome respiratorio reproductivo porcino y métodos de producción de esta.
MX2015000442A (es) Composiciones vacuna.
CY1118399T1 (el) Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c
CO2017003840A2 (es) Formulación esterilizada por calor que comprende quitosán y proceso para preparación de la misma
UY32720A (es) Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados
UY32758A (es) Composiciones y métodos para el tratamiento de infecciones ópticas, nasales u oftálmicas
UY34420A (es) ?métodos de tratamiento del virus de la hepatitis c con que de gs-7977 y ribavirina, composiciones y usos"
CL2017001595A1 (es) Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas
UA118542C2 (uk) Імуногенна сполука, що включає пептид gp41 віл, зв'язаний з білком-носієм crm197
BR112016012393A8 (pt) vacina, e, uso de uma combinação de um vírus prrs atenuado vivo e um antígeno de lawsonia intracellularis inativado
MX2016002903A (es) Composiciones inmunogenas de la glicoproteina g de los virus hendra y nipah.
CR20120166A (es) Composiciones y productos antimicrobianos
DOP2017000116A (es) Composiciones de acción prolongada de combinación y procedimientos para hepatitis c
CL2017001159A1 (es) Composiciones farmacéuticas de larga duración para la hepatitis c
AR106956A1 (es) Cepas de virus sincitial respiratorio recombinante con mutaciones en el marco de lectura abierto (orf) m2-2 que proporcionan un rango de fenotipos de atenuación
BR112015010927A2 (pt) composições de suspensão de finafloxacina